Advanced in Peripheral T-Cell Lymphoma

Hirohiko Shibayama

Osaka, JP 
Advanced in Peripheral T-Cell Lymphoma
Osaka, JP 
OverviewLocationsClinical Research

Overview

Hirohiko Shibayama practices in Osaka, Japan. Shibayama is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 124 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Peripheral T-Cell Lymphoma.

Locations

Osaka, Japan
Other Locations
Suita, Japan
Japan
Chuo, 5400006, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3

124 Total Publications

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.
Journal: Hematology (Amsterdam, Netherlands)
Published: April 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shibayama's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile